Wie hoch ist der Preis für Arch Biopartners Inc. (ARCH)

Preis für Arch Biopartners Inc. (ARCH) ist $0.73393689

Wie hoch ist die Marktkapitalisierung für Arch Biopartners Inc. (ARCH)

Marktkapitalisierung für Arch Biopartners Inc. (ARCH) ist $49.86M

Arch Biopartners Inc. (ARCH) Dividendenrendite

Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.

Jahr	Dividendenrendite	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Dividendenrendite

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Dividendenrendite	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH
Moderna, Inc. MRNA.US	0.00%	US

Unternehmen

Dividendenrendite

Land